asoprisnil
Small moleculeexperimental
Asoprisnil is a synthetic, steroidal selective progesterone receptor modulator that was under development by Schering and TAP Pharmaceutical Products for the treatment of uterine fibroids. In 2005, phase III clinical trials were discontinued due to endometrial changes in patients. — Wikipedia
Clinical trial activity
15 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
15
Phase 3
6
Phase 4
0
Earliest trial started May 1, 2000 (NCT00160446)
Timeline
Indications
Mechanism of action
- Progesterone receptorMODULATOR
PGR modulator
Development discontinued due to "endometrial changes" experienced by some patients. Is a selective progesterone receptor modulator.
Chemistry & pharmacology
Loading structure…
SMILES
COC[C@]1(OC)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(/C=N/O)cc3)C[C@@]21C- Mol. weight
- 449.59 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaAsoprisnil ↗
- ChEMBLCHEMBL267431 ↗
Also known as
- asoprisnil
- asoprisnil
- asoprisnil
- asoprisnil
- bay86-5294
- bay86-5294
- benzaldehyde, 4-((11beta, 17beta)-17-methoxy-17-(methoxymethyl)-3-oxoestra-4, 9-dien-11beta-yl)-, 1-oxime
- j867
- j867
- j867 cpd
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00156156 | Phase 3 | Nov 1, 2004 | Abbott |
| NCT00156208 | Phase 3 | Apr 1, 2004 | Abbott |
| NCT00152256 | Phase 3 | Sep 1, 2003 | Abbott |
| NCT00156195 | Phase 3 | Sep 1, 2003 | Abbott |
| NCT00150644 | Phase 2 | Jul 1, 2003 | Abbott |
| NCT00160420 | Phase 2 | Dec 1, 2002 | Abbott |
| NCT00160381 | Phase 3 | Sep 1, 2002 | Abbott |
| NCT00160433 | Phase 2 | Aug 1, 2002 | Abbott, Jenapharm |
| NCT00152269 | Phase 3 | Jul 1, 2002 | Abbott |
| NCT00288691 | Phase 2 | Nov 1, 2001 | Bayer, TAP Pharmaceuticals |
| NCT00156182 | Phase 2 | Apr 1, 2001 | Abbott |
| NCT00152295 | Phase 2 | Apr 1, 2001 | Abbott |
| NCT00152282 | Phase 2 | Sep 1, 2000 | Abbott |
| NCT00160446 | Phase 2 | May 1, 2000 | Abbott |
| NCT00160459 | Phase 2 | May 1, 2000 | Abbott |
Showing 15 of 15 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Abbott | For profit | 14 | 14 | 2 | 2000 |
| Bayer | For profit | 1 | 1 | 1 | 2001 |
| Jenapharm | For profit | 1 | 0 | 1 | 2002 |
| TAP Pharmaceuticals | For profit | 1 | 0 | 1 | 2001 |
4 organizations
Page 1 / 1